Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone

Hoffmann, Klaus; Auer, Thorsten; Stücker, Markus; Hoffmann, A.; Altmeyer, Peter

doi:10.1111/j.1468-3083.1998.tb00713.x

Cited by 34 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further clinical trials of up to 6 weeks in healthy adult volunteers15, 16, 17 and patients with psoriasis18 have found the atrophogenic potential of mometasone furoate 0.1% ointment or cream to be low. However, in two studies, mometasone furoate 0.1% ointment used for 6 weeks with occlusion in healthy adult volunteers was associated with a significantly greater incidence and severity of skin atrophy and telangiectasia than methylprednisolone aceponate 0.1% ointment9 and prednicarbate 0.1% ointment,1 but it was not as pronounced as it was for betamethasone valerate 0.1% ointment 1…”

Section: Clinical Safetymentioning

confidence: 99%

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids

Spada¹,

Barnes²,

Greive³

2018

Aust J Dermatology

View full text Add to dashboard Cite

Derivatives of hydrocortisone, such as mometasone furoate, a (2′) furoate‐17 ester with chlorine substitutions at positions 9 and 21, have been designed to improve efficacy and reduce the incidence of adverse effects. An extensive literature search of MEDLINE, Embase and other databases was conducted to review the safety and efficacy of various formulations of topical mometasone furoate. Mometasone furoate exhibits high potency with greater anti‐inflammatory activity and a longer duration of action than betamethasone. In clinical trials, mometasone furoate shows comparable or significantly better efficacy, depending on the comparator, in all indications studied in both adults and children. It is well tolerated with only transient, mild to moderate local adverse effects. It is characterised by low systemic availability due to its high lipophilicity, low percutaneous absorption and rapid hepatic biotransformation, and consequently has no significant effect on the hypothalamic‐pituitary‐adrenal axis. The molecular biotransformation of mometasone furoate in the skin results in a lower affinity with dermal cells than epidermal cells, which contributes to its low atrophogenicity. Sensitisation to mometasone furoate is low. Overall, mometasone furoate is a highly efficacious potent corticosteroid with a low risk of both local and systemic adverse effects.

show abstract

Section: Clinical Safetymentioning

confidence: 99%

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids

Spada¹,

Barnes²,

Greive³

2018

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…2,3 In clinical and experimental studies high-frequency ultrasound has been used as an established noninvasive method for the quantification of corticosteroid-induced skin atrophy. [4][5][6][7][8][9][10][11] However, because of its low resolution ultrasound determines only the dermal thickness. This parameter changes relatively late because of the slow metabolism of the collagen synthesis.…”

mentioning

confidence: 99%

Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial

Cossmann

Welzel

2006

British Journal of Dermatology

View full text Add to dashboard Cite

OCT allows a simple, fast and noninvasive in vivo measurement of the epidermal thickness. To evaluate the atrophogenic potential of corticosteroids it is more suitable than high-frequency ultrasound as epidermal thickness decreases earlier. In addition, epidermal thickness is a more sensitive indicator of steroid atrophy as the degree of thinning is much higher compared with the dermal atrophy. Profilometry might give further information; however, it would not be suitable for clinical use as the results were generally less pronounced. In the future, OCT might be useful to detect corticosteroid-induced side-effects at the beginning for monitoring the therapy.

show abstract

“…Mometasone furoate, one of these new derivatives [8], is characterized by persistent high intradermal concentrations and very low systemic availability [3]. Mometasone furoate is categorized as a class III topical corticosteroid, and its atrophogenic potential was found to be low [6,9]. Consequently, a therapeutic index of 2.0 has been attributed to this glucocorticoid [3].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Patient-Reported Outcomes of a New Mometasone Cream Treating Atopic Eczema

Ruzicka¹,

Willers

Wigger‐Alberti³

2012

Skin Pharmacol Physiol

View full text Add to dashboard Cite

This double-blind controlled phase II study was conducted to compare a newly developed formulation of mometasone furoate with a water content of 33% (Monovo® Cream) and with a smooth consistency versus the commercially available fatty cream of mometasone furoate (Ecural® Fettcreme) in terms of efficacy, cosmetic properties, and patients’ acceptance. In 20 patients with mild to moderate atopic eczema, the preparations were tested intraindividually in a randomized mode and in two comparable lesion areas. Both preparations were equally effective and well tolerated. Due to improved cosmetic properties, the new formulation was preferred by the patients when asked for preferential use. Quality of life could be improved by treating with both preparations.

show abstract

Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone

Cited by 34 publications

References 11 publications

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids

Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial

Efficacy and Patient-Reported Outcomes of a New Mometasone Cream Treating Atopic Eczema

Contact Info

Product

Resources

About